S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
66,000% upside on tiny biotech? (Ad)
FuelCell Is Back To Realistic Valuation
New Mexico reaches $500M settlement with Walgreens in opioid case
Trade Smarter: Discover Hidden Opportunities w/ A.I. (Ad)
Nigeria's central bank chief arrested after being suspended by president
American Airlines, JetBlue seek to keep some ties despite losing antitrust case
Trade Smarter: Discover Hidden Opportunities w/ A.I. (Ad)
Oregon Democratic Party to send federal officials a $500,000 donation from former FTX executive
Ukrainian President Volodymyr Zelenskyy says ‘counteroffensive, defensive actions’ taking place in war with Russia
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
66,000% upside on tiny biotech? (Ad)
FuelCell Is Back To Realistic Valuation
New Mexico reaches $500M settlement with Walgreens in opioid case
Trade Smarter: Discover Hidden Opportunities w/ A.I. (Ad)
Nigeria's central bank chief arrested after being suspended by president
American Airlines, JetBlue seek to keep some ties despite losing antitrust case
Trade Smarter: Discover Hidden Opportunities w/ A.I. (Ad)
Oregon Democratic Party to send federal officials a $500,000 donation from former FTX executive
Ukrainian President Volodymyr Zelenskyy says ‘counteroffensive, defensive actions’ taking place in war with Russia
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
66,000% upside on tiny biotech? (Ad)
FuelCell Is Back To Realistic Valuation
New Mexico reaches $500M settlement with Walgreens in opioid case
Trade Smarter: Discover Hidden Opportunities w/ A.I. (Ad)
Nigeria's central bank chief arrested after being suspended by president
American Airlines, JetBlue seek to keep some ties despite losing antitrust case
Trade Smarter: Discover Hidden Opportunities w/ A.I. (Ad)
Oregon Democratic Party to send federal officials a $500,000 donation from former FTX executive
Ukrainian President Volodymyr Zelenskyy says ‘counteroffensive, defensive actions’ taking place in war with Russia
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
66,000% upside on tiny biotech? (Ad)
FuelCell Is Back To Realistic Valuation
New Mexico reaches $500M settlement with Walgreens in opioid case
Trade Smarter: Discover Hidden Opportunities w/ A.I. (Ad)
Nigeria's central bank chief arrested after being suspended by president
American Airlines, JetBlue seek to keep some ties despite losing antitrust case
Trade Smarter: Discover Hidden Opportunities w/ A.I. (Ad)
Oregon Democratic Party to send federal officials a $500,000 donation from former FTX executive
Ukrainian President Volodymyr Zelenskyy says ‘counteroffensive, defensive actions’ taking place in war with Russia
NASDAQ:NERV

Minerva Neurosciences (NERV) Stock Forecast, Price & News

$6.96
+0.01 (+0.14%)
(As of 06/9/2023 ET)
Compare
Today's Range
$6.79
$7.10
50-Day Range
$1.62
$7.75
52-Week Range
$1.26
$15.27
Volume
89,154 shs
Average Volume
101,305 shs
Market Capitalization
$38.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00

Minerva Neurosciences MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
14.9% Upside
$8.00 Price Target
Short Interest
Bearish
6.41% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.89
Upright™ Environmental Score
News Sentiment
1.24mentions of Minerva Neurosciences in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$192,503 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.14) to ($1.33) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.81 out of 5 stars

Medical Sector

888th out of 987 stocks

Pharmaceutical Preparations Industry

440th out of 482 stocks


NERV stock logo

About Minerva Neurosciences (NASDAQ:NERV) Stock

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Receive NERV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Minerva Neurosciences and its competitors with MarketBeat's FREE daily newsletter.

NERV Stock News Headlines

Bank Collapse Causes Gold Prices to Soar
Silicon Valley Bank was the second-largest bank in American history to fail, and investors have started piling into the safety and security of gold. But if you're not taking advantage of a little-known way to invest for around $5 today, you're missing out.
America's Worst Nightmare: A Major Financial Crisis Looms
Something strange is happening in our financial system. UBS analysts predict over 50,000 retail locations may close soon. Retail giants like Walmart, Foot Locker, Bed Bath & Beyond, and Macy's are already downsizing their stores. Are you using the best technology to protect your money at all costs?
Insomnia Medication Market Forecast to 2030
See More Headlines

NERV Price History

NERV Company Calendar

Last Earnings
11/08/2021
Today
6/10/2023
Next Earnings (Estimated)
8/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NERV
Fax
N/A
Employees
9
Year Founded
2007

Price Target and Rating

Average Stock Price Forecast
$8.00
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+14.9%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$-32,110,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$41.18 million
Book Value
($3.75) per share

Miscellaneous

Free Float
5,262,000
Market Cap
$38.77 million
Optionable
Optionable
Beta
0.02

Social Links


Key Executives

  • Dr. Remy Luthringer Ph.D. (Age 62)
    Exec. Chairman & CEO
    Comp: $853.58k
  • Mr. Geoffrey Robin Race F.C.M.A. (Age 62)
    FCMA, M.B.A., MBA, Pres
    Comp: $628.46k
  • Mr. Frederick W. Ahlholm CPA (Age 57)
    CPA, Sr. VP, CFO & Sec.
    Comp: $567.49k
  • Mr. Joseph Reilly (Age 48)
    Sr. VP & COO
  • Mr. William B. Boni (Age 71)
    VP of Investor Relations & Corp. Communications
  • Prof. Michael Davidson M.D. (Age 73)
    Chief Medical Officer
  • Dr. Ramana Kuchibhatla Ph.D.
    Sr. VP and Head of R&D













NERV Stock - Frequently Asked Questions

Should I buy or sell Minerva Neurosciences stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Minerva Neurosciences in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" NERV shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NERV, but not buy additional shares or sell existing shares.
View NERV analyst ratings
or view top-rated stocks.

What is Minerva Neurosciences' stock price forecast for 2023?

2 Wall Street analysts have issued 12-month price targets for Minerva Neurosciences' shares. Their NERV share price forecasts range from $8.00 to $8.00. On average, they anticipate the company's share price to reach $8.00 in the next twelve months. This suggests a possible upside of 14.9% from the stock's current price.
View analysts price targets for NERV
or view top-rated stocks among Wall Street analysts.

How have NERV shares performed in 2023?

Minerva Neurosciences' stock was trading at $1.59 at the beginning of 2023. Since then, NERV stock has increased by 337.7% and is now trading at $6.96.
View the best growth stocks for 2023 here
.

When is Minerva Neurosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our NERV earnings forecast
.

How were Minerva Neurosciences' earnings last quarter?

Minerva Neurosciences, Inc. (NASDAQ:NERV) posted its quarterly earnings results on Monday, November, 8th. The biopharmaceutical company reported ($1.76) earnings per share for the quarter, meeting the consensus estimate of ($1.76). During the same period last year, the business posted ($1.52) earnings per share.

When did Minerva Neurosciences' stock split?

Shares of Minerva Neurosciences reverse split on the morning of Tuesday, June 21st 2022. The 1-8 reverse split was announced on Tuesday, June 21st 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, June 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

What other stocks do shareholders of Minerva Neurosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Minerva Neurosciences investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), PTC Therapeutics (PTCT), Immunomedics (IMMU), VBI Vaccines (VBIV), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Moderna (MRNA), T2 Biosystems (TTOO) and Advanced Micro Devices (AMD).

What is Minerva Neurosciences' stock symbol?

Minerva Neurosciences trades on the NASDAQ under the ticker symbol "NERV."

Who are Minerva Neurosciences' major shareholders?

Minerva Neurosciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include Group One Trading L.P. (0.00%). Insiders that own company stock include David Kupfer, Frederick W Ahlholm, Geoff Race, Heek G Jan Van, Joseph H Reilly and Remy Luthringer.
View institutional ownership trends
.

How do I buy shares of Minerva Neurosciences?

Shares of NERV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Minerva Neurosciences' stock price today?

One share of NERV stock can currently be purchased for approximately $6.96.

How much money does Minerva Neurosciences make?

Minerva Neurosciences (NASDAQ:NERV) has a market capitalization of $38.77 million and generates $41.18 million in revenue each year. The biopharmaceutical company earns $-32,110,000.00 in net income (profit) each year or ($5.49) on an earnings per share basis.

How can I contact Minerva Neurosciences?

Minerva Neurosciences' mailing address is 1601 TRAPELO ROAD SUITE 286, WALTHAM MA, 02451. The official website for the company is www.minervaneurosciences.com. The biopharmaceutical company can be reached via phone at (617) 600-7373 or via email at wboni@minervaneurosciences.com.

This page (NASDAQ:NERV) was last updated on 6/10/2023 by MarketBeat.com Staff

My Account -